OSR Health (OSRHW) Non-Current Assets (2021 - 2026)
OSR Health (OSRHW) posted Non-Current Assets of $169.3 million for Q1 2026, up 0.5% sequentially from $168.4 million in Q4 2025, and down 1.06% YoY from $171.1 million in Q1 2025.
OSR Health (OSRHW) Non-Current Assets (2021 - 2026) Analysis & Trends
OSR Health has reported Non-Current Assets for 6 years, with the latest figure at $169.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 1.06% year-over-year to $169.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $694.3 million (up 80.18% YoY) and the FY2025 annual result came in at $168.4 million, down 2.6% from the prior year.
- Non-Current Assets advanced to $169.3 million in Q1 2026 per OSRHW's latest filing, from $168.4 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $182.5 million in Q2 2025 and troughed at $1.1 million in Q4 2022.
- A 5-year average of $97.8 million and a median of $71.7 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 3223.65% in 2023, then slumped 71.35% in 2024.
- Over 5 years, Non-Current Assets stood at $1.1 million in 2022, then surged by 3223.65% to $36.6 million in 2023, then jumped by 372.37% to $172.9 million in 2024, then decreased by 2.6% to $168.4 million in 2025, then climbed by 0.5% to $169.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $169.3 million, $168.4 million, and $174.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 18.06 Bn |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn | 468.65 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | 163.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 169.26 Mn |
| Dec 31, 2025 | 168.42 Mn |
| Sep 30, 2025 | 174.09 Mn |
| Jun 30, 2025 | 182.54 Mn |
| Mar 31, 2025 | 171.08 Mn |
| Dec 31, 2024 | 172.91 Mn |
| Sep 30, 2024 | 20.89 Mn |
| Jun 30, 2024 | 20.47 Mn |
| Mar 31, 2024 | 37.21 Mn |
| Dec 31, 2023 | 36.61 Mn |
| Sep 30, 2023 | 72.05 Mn |
| Jun 30, 2023 | 71.44 Mn |
| Mar 31, 2023 | 70.63 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 700,330.00 |